rhuMAb Beta7

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Ulcerative Colitis

Phase 1

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

CompletedNCT00694980

Genentech, Inc.Ulcerative Colitis

Start: 2008-09-30End: 2012-09-30Updated: 2016-11-02

Phase 2

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

CompletedNCT01336465

Genentech, Inc.Ulcerative Colitis

Start: 2011-09-30End: 2013-06-30Updated: 2016-08-12

Related Papers

P069 Artificial intelligence (AI)-filtered Videos for Accelerated Scoring of Colonoscopy Videos in Ulcerative Colitis Clinical Trials

Journal of Crohn s and Colitis2021-05-01

P035 ETROLIZUMAB TREATMENT MODULATES SOLUBLE MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN’S DISEASE

Inflammatory Bowel Diseases2019-02-01

P395 Etrolizumab demonstrated no difference among doses in symptomatic and endoscopic-based evaluation of remission in anti-TNF-α-naïve patients in a post-hoc analysis of the phase 2 ulcerative colitis trial (EUCALYPTUS)

Journal of Crohn s and Colitis2017-01-263 citations

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

2014-05-09337 citations